Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00012

2024-02-15

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel heterocyclic PAD4 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.

chemistry, medicinal

What problem does this paper attempt to address?

Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00408

2024-09-19

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.

chemistry, medicinal
Phosphodiesterase-4(PDE4) As a Target for Anti-Inflammatory Drug Discovery: Present and Prospect

TANG Hui-fang,CHEN Ji-qiang,WANG Peng

DOI: https://doi.org/10.3321/j.issn:1000-5048.2006.01.002

2006-01-01

Abstract:Type 4 cAMP-specific phosphodiesterase(PDE4)is one of the most popular drug targets.PDE4 inhibitors exhibit efficacy for several inflammatory diseases including asthma,chronic obstructive pulmonary disease(COPD),allergic rhinitis and atopic dermatitis.In the animal models,the inhibitors show indication for arthritis and sepsis,etc.Clinical development of the first generation PDE4 inhibitors(such as rolipram and piclamilast)has been discontinued due to the side-effects such as emesis and vomiting.Several of the second generation PDE4 inhibitors(such as cilomailast and roflumilast)are currently under development.However,they are still not devoid of the emetic side-effect.As a result,their doses sizes are stricitly limited.Although PDE4 family comprises four subtypes,current PDE4 inhibitors in general do not distinguish between various subtypes.Recently,there has been a significant progress in the understanding of the action of the PDE4 subtypes.Inhibitors of specific PDE4 subtype(s) may have reduced side-effect potential while maintaining the anti-inflammatory activity,and hence providing significant improvement over current PDE4 inhibitors.
Identification of novel PAD4 inhibitors using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulations

Vivek Malik,Trashgim Mulosmani

DOI: https://doi.org/10.26434/chemrxiv-2024-pwk55

2024-10-16

Abstract:Protein arginine deiminase 4 (PAD4) is a member of the PAD family of enzymes which catalyze citrullination, or the conversion of the amino acid arginine to citrulline. Overexpression and dysregulation of PAD4 is implicated in the onset and progression of a variety of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA). Thus, PAD4 inhibition via small molecules is an attractive therapeutic avenue. We utilized pharmacophore-based virtual screening of databases including over 120 million commercially available compounds to identify novel small molecule reversible inhibitors of PAD4. Molecular docking and ADME filtering identified our top three compounds that showed high binding affinity and promising ADME/Tox properties. Molecular dynamics (MD) simulations and post-MD analysis metrics such as RMSD, RMSF and Rg were carried out on the final hits to determine the stability of the complexes. All final hits outperform previously discovered reversible PAD4 inhibitors by docking score and ADME properties. Ultimately, MolPort 010-719-973 showed the most promising docking scores, residue interactions, stability, and binding energy as compared to the reference compound. Thus, we identify a novel reversible PAD4 inhibitor that may prove useful for the treatment of RA and can be used as a scaffold to design more potent PAD4 inhibitors.

Chemistry
Novel Phosphorylpurinone Compounds for Treating Cancer

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00087

2024-03-08

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel phosphorylpurinone compounds as TLR7 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

chemistry, medicinal
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00088

2024-03-08

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel PCSK9 inhibitors, pharmaceutical compositions, use of such compounds in treating cardiovascular diseases, and processes for preparing such compounds.

chemistry, medicinal
Novel HSD17B13 Inhibitors for Treating Liver Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00195

2024-06-19

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel HSD17B13 inhibitors, pharmaceutical compositions, use of such compounds in treating liver diseases, and processes for preparing such compounds.

chemistry, medicinal
Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00044

2024-02-14

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel pyrrolidinone derivatives as NIK inhibitors, pharmaceutical compositions, use of such compounds in treating inflammatory and autoimmune diseases, and processes for preparing such compounds.

chemistry, medicinal
Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Jing Li,Nan Zhou,Wen Liu,Jianzong Li,Yu Feng,Xiaoyun Wang,Chuanfang Wu,Jinku Bao

DOI: https://doi.org/10.1080/07391102.2015.1070749

2016-01-01

Abstract:cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a key role in many physiological processes. PDE4B which can reduce the cAMP level by hydrolyzing cAMP to 5-AMP has become a therapeutic target for the treatment of human diseases such as respiratory disorders, inflammation diseases, neurological and psychiatric disorders. However, the use of currently available PDE4B inhibitors is restricted due to serious side effects caused by targeting PDE4D. Hence, we are attempting to find out subfamily-selective PDE4B inhibitors from natural products, using computer-aided approaches such as virtual screening, docking, and molecular dynamics simulation. Finally, four potential PDE4B-selective inhibitors (ZINC67912770, ZINC67912780, ZINC72320169, and ZINC28882432) were found. Compared to the reference drug (roflumilast), they scored better during the virtual screening process. Binding free energy for them was -317.51, -239.44, -215.52, and -165.77kJ/mol, better than -129.05kJ/mol of roflumilast. The pharmacophore model of the four candidate inhibitors comprised six features, including one hydrogen bond donor, four hydrogen bond acceptors, and one aromatic ring feature. It is expected that our study will pave the way for the design of potent PDE4B-selective inhibitors of new drugs to treat a wide variety of diseases such as asthma, COPD, psoriasis, depression, etc.
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00011

2024-02-15

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel fused triazole compounds as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating neurodegenerative, autoimmune, and inflammatory diseases, and processes for preparing such compounds.

chemistry, medicinal
Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy

Santhiya Panchalingam,Manikandan Jayaraman,Jeyakanthan Jeyaraman,Govindaraju Kasivelu

DOI: https://doi.org/10.1016/j.abb.2024.110164

2024-09-24

Abstract:Peptidylarginine deiminase type4 (PAD4) is a pivotal pro-inflammatory protein within the human immune system, intricately involved in both inflammatory processes and immune responses. Its role extends to the generation of diverse immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. PAD4 has recently garnered attention due to its association with a spectrum of inflammatory and autoimmune disorders, notably rheumatoid arthritis (RA). Mutations in the PAD4 gene, leading to the conversion of arginine to citrulline, have emerged as significant factors in the pathogenesis of RA and related conditions. As a calcium-dependent enzyme, PAD4 is central to the citrullination process, a crucial post-translational modification implicated in disease pathophysiology. Its critical role in autoimmune disorders and inflammation makes PAD4 a prime candidate for therapeutic intervention in RA. Inhibiting PAD4 presents a promising avenue for mitigating inflammatory responses and curtailing joint degradation and impairment. To explore its therapeutic potential, a structure-based virtual screening (SBVS) approach was employed, harnessing an array of marine natural products (MNPs) sourced from databases such as CMNPD, MNPD, and Seaweed. Notably, MNPD10752, CMNPD12680, and CMNPD2751 emerged as potential hit molecules, exhibiting adherence to essential pharmacokinetic properties and favorable toxicity profiles. Quantum mechanics studies using density functional theory (DFT) calculations revealed the inhibitory potential of these identified natural products. Further structural elucidation through molecular dynamics simulations (MDS) and principal component-based free energy landscape (FEL) analysis shed light on the stability of MNP-bound PAD4 complexes. In conclusion, this computational study serves as a stepping stone for further experimental evaluation, aiming to explore the potential of MNPs in addressing PAD4-related human pathologies.
Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential

Dhritiman Roy,Shivaramakrishnan Balasubramanian,Praveen Thaggikuppe Krishnamurthy,Piyong Sola,Emdormi Rymbai

DOI: https://doi.org/10.1007/s10571-023-01349-1

Abstract:Clinicians and researchers are exploring safer and novel treatment strategies for treating the ever-prevalent Parkinson's disease (PD) across the globe. Several therapeutic strategies are used clinically for PD, including dopamine replacement therapy, DA agonists, MAO-B blockers, COMT blockers, and anticholinergics. Surgical interventions such as pallidotomy, particularly deep brain stimulation (DBS), are also employed. However, they only provide temporal and symptomatic relief. Cyclic adenosine monophosphate (cAMP) is one of the secondary messengers involved in dopaminergic neurotransmission. Phosphodiesterase (PDE) regulates cAMP and cGMP intracellular levels. PDE enzymes are subdivided into families and subtypes which are expressed throughout the human body. PDE4 isoenzyme- PDE4B subtype is overexpressed in the substantia nigra of the brain. Various studies have implicated multiple cAMP-mediated signaling cascades in PD, and PDE4 is a common link that can emerge as a neuroprotective and/or disease-modifying target. Furthermore, a mechanistic understanding of the PDE4 subtypes has provided perceptivity into the molecular mechanisms underlying the adverse effects of phosphodiesterase-4 inhibitors (PDE4Is). The repositioning and development of efficacious PDE4Is for PD have gained much attention. This review critically assesses the existing literature on PDE4 and its expression. Specifically, this review provides insights into the interrelated neurological cAMP-mediated signaling cascades involving PDE4s and the potential role of PDE4Is in PD. In addition, we discuss existing challenges and possible strategies for overcoming them.
Identification of novel PAD2 inhibitors using pharmacophore-based virtual screening, molecular docking, and MD simulation studies

Prakash Jha,Prerna Rajoria,Priya Poonia,Madhu Chopra

DOI: https://doi.org/10.1038/s41598-024-78330-5

IF: 4.6

2024-11-22

Scientific Reports

Abstract:In the realm of epigenetic regulation, Protein arginine deiminase 2 (PAD2) stands out as a therapeutic target due to its significant role in neurological disorders, rheumatoid arthritis (RA), multiple sclerosis (MS), and various cancers. To date, no in silico studies have focused on PAD2 for lead compound identification. Therefore, we conducted structure-based pharmacophore modeling, virtual screening, molecular docking, molecular dynamics (MD) simulations, and essential dynamics studies using PCA and free energy landscape analyses to identify repurposed drugs and selective inhibitors against PAD2. The best pharmacophore model, 'Pharm_01,' had a selectivity score of 10.485 and an excellent ROC curve quality of 0.972. Pharm1 consisted of three hydrogen bond donors (HBD) and two hydrophobic (Hy) features (DDDHH). A virtual screening of about 9.2 million compounds yielded 2575 hits using a fit value threshold of 2.5 and drug-likeness criteria. Molecular docking identified the top ten molecules, which were verified using MD simulations. Stability was verified using MM-PBSA studies, whereas conformational differences were investigated using PCA and free energy landscape analyses. Two hits (Leads 1 and 2) from the DrugBank dataset showed promise for repurposing as PAD2 inhibitors, while one hit compound (Lead 8) from the ZINC database emerged as a novel PAD2 inhibitor. These findings indicate that the discovered compounds may be potent PAD2 inhibitors, necessitating additional preclinical and clinical research to produce viable treatments for cancer and neurological disorders.

multidisciplinary sciences
PDE4D: A Multipurpose Pharmacological Target

Matteo Lusardi,Federica Rapetti,Andrea Spallarossa,Chiara Brullo

DOI: https://doi.org/10.3390/ijms25158052

2024-07-24

Abstract:Phosphodiesterase 4 (PDE4) enzymes catalyze cyclic adenosine monophosphate (cAMP) hydrolysis and are involved in a variety of physiological processes, including brain function, monocyte and macrophage activation, and neutrophil infiltration. Among different PDE4 isoforms, Phosphodiesterases 4D (PDE4Ds) play a fundamental role in cognitive, learning and memory consolidation processes and cancer development. Selective PDE4D inhibitors (PDE4Dis) could represent an innovative and valid therapeutic strategy for the treatment of various neurodegenerative diseases, such as Alzheimer's, Parkinson's, Huntington's, and Lou Gehrig's diseases, but also for stroke, traumatic brain and spinal cord injury, mild cognitive impairment, and all demyelinating diseases such as multiple sclerosis. In addition, small molecules able to block PDE4D isoforms have been recently studied for the treatment of specific cancer types, particularly hepatocellular carcinoma and breast cancer. This review overviews the PDE4DIsso far identified and provides useful information, from a medicinal chemistry point of view, for the development of a novel series of compounds with improved pharmacological properties.
Discovery, Characterization, and Structure of a Cell Active PAD2 Inhibitor Acting through a Novel Allosteric Mechanism

Laura J. Byrnes,Won Young Choi,Paul Balbo,Mary Ellen Banker,Jeanne Chang,Shi Chen,Xuemin Cheng,Yang Cong,Jeff Culp,Hongxia Di,Matt Griffor,Justin Hall,Xiaoyun Meng,Barry Morgan,James J. Mousseau,Jennifer Nicki,Thomas O’Connell,Simeon Ramsey,Alex Shaginian,Suman Shanker,John Trujillo,Jinqiao Wan,Fabien Vincent,Stephen W. Wright,Felix Vajdos

DOI: https://doi.org/10.1021/acschembio.4c00397

IF: 4.634

2024-09-25

ACS Chemical Biology

Abstract:Peptidyl arginine deiminases (PADs) are important enzymes in many diseases, especially those involving inflammation and autoimmunity. Despite many years of effort, developing isoform-specific inhibitors has been a challenge. We describe herein the discovery of a potent, noncovalent PAD2 inhibitor, with selectivity over PAD3 and PAD4, from a DNA-encoded library. The biochemical and biophysical characterization of this inhibitor and two noninhibitory binders indicated a novel, Ca^(2+) competitive...

biochemistry & molecular biology
Novel Azepino[4,5- b ]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00356

2024-09-19

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel azepino[4,5-b]indolone as cGAS inhibitors, pharmaceutical compositions, use of such compounds in treating immune-mediated diseases and processes for preparing such compounds.

chemistry, medicinal
Structure–Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy

Yijiang Jia,Renbo Jia,Ayijiang Taledaohan,Yanming Wang,Yuji Wang

DOI: https://doi.org/10.3390/pharmaceutics16030335

IF: 6.525

2024-02-29

Pharmaceutics

Abstract:Protein arginine deiminase 4 (PAD4) plays an important role in cancer progression by participating in gene regulation, protein modification, and neutrophil extracellular trap (NET) formation. Many reversible and irreversible PAD4 inhibitors have been reported recently. In this review, we summarize the structure–activity relationships of newly investigated PAD4 inhibitors to bring researchers up to speed by guiding and describing new scaffolds as optimization and development leads for new effective, safe, and selective cancer treatments. In addition, some recent reports have shown evidence that PAD4 inhibitors are expected to trigger antitumor immune responses, regulate immune cells and related immune factors, enhance the effects of immune checkpoint inhibitors, and enhance their antitumor efficacy. Therefore, PAD4 inhibitors may potentially change tumor immunotherapy and provide an excellent direction for the development and clinical application of immunotherapy strategies for related diseases.

pharmacology & pharmacy
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00119

2024-04-18

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel isoxazolidines as RIPK1 inhibitors, pharmaceutical compositions, use of such compounds in treating Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), and processes for preparing such compounds.

chemistry, medicinal
Computer-Aided Design and Biological Evaluation of Diazaspirocyclic D4R Antagonists

Caleb A H Jones,Benjamin P Brown,Daniel C Schultz,Julie Engers,Valerie M Kramlinger,Jens Meiler,Craig W Lindsley

DOI: https://doi.org/10.1021/acschemneuro.4c00086

2024-06-19

Abstract:Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, resulting in motor dysfunction. Current treatments are primarily centered around enhancing dopamine signaling or providing dopamine replacement therapy and face limitations such as reduced efficacy over time and adverse side effects. To address these challenges, we identified selective dopamine receptor subtype 4 (D4R) antagonists not previously reported as potential adjuvants for PD management. In this study, a library screening and artificial neural network quantitative structure-activity relationship (QSAR) modeling with experimentally driven library design resulted in a class of spirocyclic compounds to identify candidate D4R antagonists. However, developing selective D4R antagonists suitable for clinical translation remains a challenge.
Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis

Zhendong Song,Yi-You Huang,Ke-Qiang Hou,Lu Liu,Feng Zhou,Yue Huang,Guohui Wan,Hai-Bin Luo,Xiao-Feng Xiong

DOI: https://doi.org/10.1021/acs.jmedchem.1c02058

IF: 8.039

2022-02-21

Journal of Medicinal Chemistry

Abstract:Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and phosphodiesterase 4 (PDE4) is an effective target for the treatment of inflammatory diseases such as psoriasis. Toddacoumalone is a natural PDE4 inhibitor with moderate potency and imperfect drug-like properties. To discover novel and potent PDE4 inhibitors with considerable druggability, a series of toddacoumalone derivatives were designed and synthesized, leading to the compound (2R,4S)-6-ethyl-2-(2-hydroxyethyl)-2,8-dimethyl-4-(2-methylprop-1-en-1-yl)-2,3,4,6-tetrahydro-5H-pyrano[3,2-c][1,8]naphthyridin-5-one (33a) with high inhibitory potency (IC50 = 3.1 nM), satisfactory selectivity, favorable skin permeability, and a well-characterized binding mechanism. Encouragingly, topical administration of 33a exhibited remarkable therapeutic effects in an imiquimod-induced psoriasis mouse model.

chemistry, medicinal
Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As Potential PDE4 Inhibitors.

Gaopeng Song,Dongsheng Zha,Dekun Hu,Yasheng Li,Hongwei Jin,Zining Cui

DOI: https://doi.org/10.1016/j.bmcl.2015.08.043

IF: 2.94

2015-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:The design, synthesis, and biological evaluation of new phosphodiesterase type 4 (PDE4) inhibitors, which possessed 7-(cyclopentyloxy)-6-methoxy 1,2,3,4-tetrahydroisoquinoline ring, were described. Compound 8 [(7-cyclopentyloxy)-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)(4-hydroxy-3-methoxy-phenyl)methanone] showed the best inhibitory activity and good selectivity against PDE4B. The docking results showed that the catechol diether moiety of compound 8 played a key role to form integral hydrogen bonds with PDE4B protein while the rest part of the molecule extended into the catalytic domain to block the access of cAMP and formed the foundation for inhibition of PDE4. Compound 8 would be great promise as a hit compound for further study based on the preliminary structure–activity relationship and molecular modeling studies.

Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases

Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases

Phosphodiesterase-4(PDE4) As a Target for Anti-Inflammatory Drug Discovery: Present and Prospect

Identification of novel PAD4 inhibitors using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulations

Novel Phosphorylpurinone Compounds for Treating Cancer

Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases

Novel HSD17B13 Inhibitors for Treating Liver Diseases

Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases

Discover Natural Compounds As Potential Phosphodiesterase-4B Inhibitors Via Computational Approaches

Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases

Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy

Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential

Identification of novel PAD2 inhibitors using pharmacophore-based virtual screening, molecular docking, and MD simulation studies

PDE4D: A Multipurpose Pharmacological Target

Discovery, Characterization, and Structure of a Cell Active PAD2 Inhibitor Acting through a Novel Allosteric Mechanism

Novel Azepino[4,5- b ]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases

Structure–Activity Relationship of PAD4 Inhibitors and Their Role in Tumor Immunotherapy

Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis

Computer-Aided Design and Biological Evaluation of Diazaspirocyclic D4R Antagonists

Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As Potential PDE4 Inhibitors.